Defunct Company
Total Trials
9
As Lead Sponsor
8
As Collaborator
1
Total Enrollment
271
NCT02127190
Study of CXA-10 in Healthy Volunteers
Phase: Phase 1
Role: Lead Sponsor
Start: Apr 30, 2014
Completion: Dec 31, 2014
NCT02248051
Open-Label Safety, Tolerability, PK Study of IV CXA-10 Emulsion in Subjects in Chronic Kidney Injury
Start: Sep 30, 2014
Completion: Sep 30, 2015
NCT02313064
Oral CXA-10 Study in Healthy Volunteers
Start: Jan 31, 2015
Completion: Jun 30, 2015
NCT02460146
PK and PD of Sequential Multiple Ascending, Repeat Doses of Oral CXA-10 in Healthy Obese Male Subjects
Start: Apr 30, 2015
Completion: Oct 31, 2015
NCT02547402
A Study of the PK Interaction of CXA-10 With Pravastatin and Vytorin® in Healthy Males
Start: Dec 31, 2015
Completion: Feb 29, 2016
NCT03422510
FIRSTx - A Study of Oral CXA-10 in Primary Focal Segmental Glomerulosclerosis (FSGS)
Phase: Phase 2
Start: Apr 15, 2018
Completion: Jul 31, 2020
NCT03449524
PRIMEx - A Study of 2 Doses of Oral CXA-10 in Pulmonary Arterial Hypertension (PAH)
Start: Aug 1, 2018
Completion: Aug 5, 2020
NCT04053543
CXA-10 Study in Subjects With Pulmonary Arterial Hypertension
Start: Aug 9, 2019
Completion: Aug 12, 2020
NCT04125745
Oral CXA-10 in Pulmonary Arterial Hypertension
Role: Collaborator
Start: Oct 31, 2019
Completion: Dec 1, 2020